These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing. Banka SS; Thachil R; Levine A; Lin H; Kaafarani H; Lee J Am J Health Syst Pharm; 2017 Jun; 74(12):898-903. PubMed ID: 28432049 [TBL] [Abstract][Full Text] [Related]
11. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy. Rhodes T; Norquist JM; Sisk CM; McQuarrie K; Trovato A; Liao J; Miller T; Maccubbin D; Watson DJ Int J Clin Pract; 2013 Dec; 67(12):1238-46. PubMed ID: 24102896 [TBL] [Abstract][Full Text] [Related]
12. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324 [TBL] [Abstract][Full Text] [Related]
13. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Norquist JM; Watson DJ; Yu Q; Paolini JF; McQuarrie K; Santanello NC Curr Med Res Opin; 2007 Jul; 23(7):1549-60. PubMed ID: 17559750 [TBL] [Abstract][Full Text] [Related]
14. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. Mills E; Prousky J; Raskin G; Gagnier J; Rachlis B; Montori VM; Juurlink D BMC Clin Pharmacol; 2003 Nov; 3():4. PubMed ID: 14614780 [TBL] [Abstract][Full Text] [Related]
15. The mechanism and mitigation of niacin-induced flushing. Kamanna VS; Ganji SH; Kashyap ML Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622 [TBL] [Abstract][Full Text] [Related]
16. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Jacobson TA Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295 [TBL] [Abstract][Full Text] [Related]
17. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880 [TBL] [Abstract][Full Text] [Related]
18. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial. Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937 [TBL] [Abstract][Full Text] [Related]
20. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Davidson MH Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]